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Hyperendemic circulation of all four types of dengue virus (DENV-1-4) has expanded glob-
ally, fueling concern for increased incidence of severe dengue. While the majority of DENV
infections are subclinical, epidemiologic studies suggest that type-cross-reactive immunity
can influence disease outcome in subsequent infections. The mechanisms controlling these
differential clinical outcomes remain poorly defined.
Methodology/Principal findings
Blood samples were collected from a cohort of school-aged Thai children who subsequently
experienced a subclinical DENV infection or developed dengue illness. PBMC collected
prior to infection were stimulated in vitro with DENV and the secretion of 30 cytokines was
measured using a multiplexed, bead-based array. Significant differences were found in cyto-
kine production based on both the type of DENV used for stimulation and the occurrence of
clinical illness. Secretion of IL-15 and MCP-1 was significantly higher by PBMC of subjects
who later developed symptomatic DENV infection. In addition, IL-6 was produced by PBMC
from all subjects who subsequently developed symptomatic infection, versus 59% of sub-
jects who had subclinical infection. Secretion of IL-12, IL-2R, MIP-1α, RANTES, GM-CSF,
and TNFα was significantly lower by PBMC from subjects with symptomatic infection.
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Conclusions/Significance
These data demonstrate significant differences in pre-existing immune responses to
DENV associated with the clinical outcome of subsequent infection. The finding of higher
levels of some cytokines in subjects with symptomatic infection and higher levels of other
cytokines in subjects with subclinical infection supports the existence of both protective
and pathologic immune profiles. Clinical-immunological correlations identified in the con-
text of natural DENV infection may be useful for evaluating immune responses to dengue
vaccines.
Author summary
Dengue is one of the most prevalent mosquito-borne infectious diseases worldwide. It is
caused by one of four viruses, types 1–4, and ranges in severity from subclinical (mild or
no symptoms) to dengue fever (febrile illness with headache and bone pain), or less fre-
quently, dengue hemorrhagic fever, where patients experience leaky blood vessels, some-
times significant bleeding, and may be severe enough to cause death. While many risk
factors have been associated with development of severe dengue, sequential infection with
different virus types is a major factor, implying that the immune response generated after
an initial infection is partly responsible for making subsequent exposure clinically worse.
This study sought to identify profiles of immune markers that correlate with increased or
decreased risk of dengue. Using samples from individuals ~5 months prior to dengue
virus infection, who later experienced either subclinical infection or overt disease, we
modeled virus exposure in vitro and compared the production of various immune pro-
teins between the two outcome groups. Three of the proteins studied were produced at
higher levels by subjects who subsequently had dengue, and six of the proteins were pro-
duced at higher levels by subjects who subsequently had subclinical infection. These
results help define what constitutes beneficial versus potentially harmful immune
responses, aiding in the design of effective dengue vaccines.
Introduction
Infection with any of the four types of dengue virus (DENV-1-4) can lead to a range of out-
comes, from asymptomatic or subclinical infection to classical dengue fever (DF), dengue
hemorrhagic fever (DHF), or, the most severe outcome, dengue shock syndrome (DSS). The
majority of DENV infections have been shown to result in subclinical outcomes [1, 2]. Patients
with DHF/DSS are most often infants born to DENV-immune mothers or individuals
experiencing a secondary DENV infection, indicating a role for pre-existing DENV immunity
in exacerbating dengue disease [3]. A major challenge for researchers has been identifying the
specific immunologic factor(s) that contribute individually or in concert to dengue pathology
or protection from disease.
Amongst the immune markers studied, higher levels of particular cytokines and chemo-
kines have been found in the sera of subjects with severe dengue compared to mild disease. A
number of pro-inflammatory cytokines in particular have been implicated in severe dengue,
including TNFα, IFNγ, IL-18, IL-1β, and IL-6 [4–6]. In most of those studies, sera or PBMC
obtained during or after secondary DENV infection were tested. PBMC obtained prior to
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infection have typically not been available to determine whether pre-existing immune profiles
could predict whether an individual developed subsequent subclinical infection or severe
dengue.
Through a unique cohort study in Thailand, school-age children were subjected to active,
school absence-based surveillance, and routine blood samples were obtained before and after
the peak DENV transmission season [1, 7, 8]. The study design allowed detection of DENV
seroconversions, i.e., a four-fold or greater increase in anti-DENV antibody titer between pre-
and post-season blood draws, in the presence or absence of overt, clinically relevant illness
(referred to hereafter as symptomatic and subclinical infections, respectively). In previously
published studies of this school-based cohort, memory T cell responses in pre-exposure PBMC
were evaluated. Higher frequencies of DENV–specific IFNγ- and IL-2-producing T cells were
reported among schoolchildren who subsequently developed subclinical infection, compared
with those who developed symptomatic secondary DENV infection [9]. Those data suggested
a link between cytokine-producing T cells and subsequent mild or subclinical illness. In the
current study, we extended our analysis of cytokine production associated with the clinical
outcome of subsequent DENV infection by stimulating pre-infection PBMC samples with live




Written informed consent was obtained from the parents/guardians of all subjects, and the
clinical investigation was conducted according to the principles expressed in the Declaration
of Helsinki. These studies were approved by the institutional review boards at the University
of Massachusetts Medical School, the Ministry of Public Health in Thailand, and the Human
Subjects Research Review Board for the Commanding General of the US Army Medical
Research and Material Command.
Specimens
Blood specimens were obtained from a prospective cohort of school-aged children in Kam-
phaeng Phet, Thailand, which has been described previously [1, 7, 8]. Briefly, plasma samples
were collected from enrolled subjects in January, June, August, and November and tested by
hemagglutination inhibition (HI) assay. A�4-fold increase in anti-DENV HI titer between
the January sample (pre) and any of the subsequent routine samples (post) was used to identify
seroconversions. Study participants were also monitored for school absences associated with
fever from June to November. Seroconversions which occurred without school-related absen-
teeism were defined as subclinical infections, and those which occurred with school-related
absenteeism and which were associated with symptomatic laboratory-confirmed DENV infec-
tions during the corresponding period were defined as symptomatic infections. Clinical ill-
nesses were classified according to the 1997 WHO guidelines [10]. DENV infection was
defined by virus isolation and/or detection of virus by reverse transcriptase polymerase chain
reaction (RT-PCR) in acute serum samples and dengue IgM/IgG enzyme immunoassay (EIA)
or HI assays against all 4 DENV types, as previously described [7]. Primary infection was
defined by an IgM-to-IgG ratio of�1.8 by EIA in the early convalescent sera obtained from
symptomatic individuals [7]. Plaque reduction neutralization test (PRNT) assays were per-
formed as previously described [11] on all subjects with positive HI titers.
Pre-exposure cytokine profiles in dengue
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In vitro stimulation and culture
Cryopreserved PBMC were shipped from Thailand on dry ice to the US and stored in liquid
nitrogen until testing. Vials of PBMC were thawed and counted. PBMC (100,000 cells/well)
were seeded into a 96-well plate in 200 μL/well RPMI 1640 medium (Gibco, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (FBS; Sigma Immunochemicals, St. Louis,
MO, USA), 200 mM L-glutamine (Gibco), and 100 U/mL penicillin/streptomycin (Gibco) and
stimulated with 1:1000 anti-CD3 (clone 12F6; a gift generously provided by Dr. Johnson
Wang), 1.2 μL/well uninfected Vero cell supernatant (negative control), or live DENV-1, live
DENV-2, live DENV-3, or live DENV-4, each at a multiplicity of infection (MOI) of 1. The
viruses used for stimulation were DENV-1 strain WP-74 (titer, 6.96 x 106 plaque-forming
units [PFU]/mL), DENV-2 strain S16803 (titer, 1.4 x 109 PFU/mL), DENV-3 strain CH53489
(titer, 8.6 x 107 PFU/mL), and DENV-4 strain 341750 (titer, 5.8 x 108 PFU/mL), all of which
were propagated in Vero cells. Each stimulation condition was performed in triplicate. The
stimulated PBMC were maintained in culture for 6–7 days, at which time the supernatants
were harvested, spun down to clear debris, and frozen at -20˚C until analysis.
Cytokine analysis
The Human Cytokine 30-plex Panel kit (LHC6003, Invitrogen, Life Technologies, Grand
Island, NY, USA) was used to determine the concentration of 30 different cytokines and che-
mokines present in the tissue culture supernatant samples, including EGF, Eotaxin, FGF-basic,
G-CSF, GM-CSF, HGF, IFNα, IFNγ, IL-1RA, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-10, IL-12 (p40/p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIG, MIP-1α, MIP-1β, RANTES,
TNFα, and VEGF. The kit was used according to the manufacturer’s instructions. Briefly, the
frozen tissue culture samples were thawed, plated undiluted (in duplicate) onto 96-well Multi-
Screen HTS filter plates (MSBVS1210; EMD Millipore Corp., Billerica, MA, USA) containing
30-plex, antibody-coated beads, and incubated on a shaker platform (MixMate; Eppendorf,
Hauppauge, NY, USA) at 550 rpm for 2 hours. The wells were then washed using a Multi-
Screen HTS Vacuum Manifold (Millipore), and the analyte-bound beads were tagged with bio-
tin-conjugated antibodies, washed, and visualized with streptavidin-conjugated phycoerythrin
(PE). The data were acquired on a Luminex 200 instrument (Luminex Corp., Austin, TX,
USA) and analyzed using Luminex 100 Integrated System 2.3 software (Luminex Corp.). Pro-
tein standards were provided in the kit, and standard curves were generated with eight stan-
dard dilutions (undiluted, 1:3, 1:9, 1:27, 1:81, 1:243, 1:729, 1:2187) in RPMI/10% FBS.
Intracellular cytokine staining (ICS)
ICS assays were performed in parallel with the in vitro stimulation and culture assays described
above. Cryopreserved PBMC were thawed, counted, and approximately 0.2-1x106 viable cells
(median, 0.5x106; the number of cells varied from subject-to-subject but were the same for all
stimulation conditions for a given subject) were plated into each well of a 96-well plate. Cells
were stimulated with a 1:40 dilution of inactivated antigen (supernatant from glutaraldehyde-
treated and lysed Vero cells uninfected [negative control] or infected with DENV-1, DENV-2,
DENV-3, or DENV-4, as previously described [12]) in complete RPMI/10% FBS medium at
37˚C. After overnight incubation (approximately 12 hours), protein transport inhibitors
(Golgi Plug/Stop, BD Biosciences) were added and the cells incubated at 37˚C for an additional
6 hours. The cells were then washed and stained with LIVE/DEAD Aqua (Invitrogen) before
fixing and permeabilizing in CytoFix/CytoPerm (BD Biosciences), resuspending in Perm
Wash Buffer (BD Biosciences), and adding the cells to a BD Lyoplate (623668; BD Biosci-
ences). The Lyoplate contained a pre-mixed cocktail of antibodies: anti-CD3-V450, anti-IFNγ-
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Alexa Fluor 488, anti-IL-2-PE, anti-CD4-PerCP-Cy5.5, anti-TNFα-PE-Cy7, and anti-
CD8-APC-H7. The cells were incubated with the antibody cocktail at room temperature for 30
minutes. Data were acquired on an LSR II flow cytometer (BD Biosciences) and analyzed
using FlowJo v9 software (Tree Star, Inc.).
Statistical analysis
Standard curves were generated for each of the 30 analytes using a five-parameter logistic
curve fit and 1/y2 weighted function by the Luminex 100 Integrated System 2.3 software. The
data were then exported and statistically analyzed using SAS 9.4 software (SAS Institute, Cary,
NC). The non-parametric Wilcoxon rank-sum test was used to compare cytokine production
between subjects with subclinical and symptomatic infections. A P value <0.05 was considered
to be statistically significant.
Results
We identified 51 subjects who had DENV seroconversions during 1998 for this study, as deter-
mined by a 4-fold rise in HI titer to at least one DENV type (Table 1). Of these, 29 subjects
experienced no overt clinical illness (subclinical infections) and 22 had illnesses that resulted
in school absenteeism (symptomatic infections), 3 of which were hospitalized. No significant
differences were found between subjects who experienced subclinical versus symptomatic
infections with regard to age (mean [range], 10.2 [8–13] years and 9.5 [7–12] years, respec-
tively) or sex (M:F ratio, 1.07 and 1.75, respectively). While no blood samples were available
from subjects with subclinical infections at the time of exposure, acute samples from those
with symptomatic infections showed a predominance of infection with DENV-3 followed by
DENV-1; a single DENV-2 infection was detected and no DENV-4 infections. Five samples
were negative by PCR, therefore the infecting DENV type is not known for those subjects.
DENV-specific neutralizing antibodies (NAb) were undetectable in 22 subjects prior to the
1998 dengue season (S1 Table). However, NAb profiles assessed after the dengue season were
predominantly multi-typic, characteristic of a secondary-type antibody response. In symptom-
atic subjects, IgM/IgG EIA titers also indicated the occurrence of secondary infections in all
but one case, despite some of the subjects having no anti-DENV NAb titers at the beginning of
the year. These results indicate that most subjects had prior exposure to DENV.
PBMC were collected from all subjects in January, prior to the dengue season, and cryopre-
served. The time interval between the pre-exposure sample and DENV infection varied from
subject-to-subject, but on average was 163 (range, 121–207) days to the first day of illness for
symptomatic subjects. The time interval between the pre-exposure sample and the first sample
with a positive HI titer was on average 218 (range, 106–306) days for subclinical subjects and
189 (range, 119–280) days for symptomatic subjects. This suggests subclinical infections
occurred on a similar timescale as symptomatic infections.
For this study, we wanted to compare the cell-derived cytokine profiles elicited from those
who went on to experience subclinical versus symptomatic DENV infections to determine
whether particular profiles could predict subsequent clinical outcome. To do this, the pre-
exposure PBMC samples were thawed and placed in separate cultures with each of the four
types of (live) DENV. The tissue culture supernatants were collected after 1 week and subjected
to a multiplexed analysis of 30 different cytokines, chemokines, and growth factors (Fig 1 and
S1 Fig).
Using this assay format we found undetectable or very low levels of EGF, Eotaxin, FGF-
basic, G-CSF, IL-1β, and IL-4 overall, and minimal DENV-specific production (detected in
five or fewer subjects, <10% of the study cohort) of HGF, IFNα, IL-7, IL-10, IL-13, and IL-17
Pre-exposure cytokine profiles in dengue
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Table 1. Characteristics of the study population.
Subject No. HI Titer (pre)a HI Titer (post)b Clinical Outcome DV Type
(PCR)DV-1 DV-2 DV-3 DV-4 DV-1 DV-2 DV-3 DV-4
1 <10 <10 <10 <10 40 40 80 80 Subclinical - -
2 <10 <10 <10 <10 20 40 40 40 Subclinical - -
3 <10 <10 10 <10 1280 1280 1280 2560 Subclinical - -
4 <10 <10 <10 <10 320 640 320 20481 Subclinical - -
5 10 <10 10 10 40 20 40 40 Subclinical - -
6 10 20 10 10 20 40 40 40 Subclinical - -
7 <10 <10 <10 <10 10 20 80 20 Subclinical - -
8 <10 <10 <10 <10 320 320 640 640 Subclinical - -
9 <10 <10 <10 <10 1280 640 1280 640 Subclinical - -
10 <10 <10 <10 <10 80 80 80 80 Subclinical - -
11 <10 <10 10 <10 320 640 1280 1280 Subclinical - -
12 <10 <10 <10 <10 80 80 80 320 Subclinical - -
13 10 10 20 10 1280 640 640 640 Subclinical - -
14 <10 <10 <10 <10 640 1280 2560 1280 Subclinical - -
15 20 20 <10 <10 160 320 320 80 Subclinical - -
16 <10 <10 10 10 40 40 40 40 Subclinical - -
17 <10 <10 10 <10 320 320 320 320 Subclinical - -
18 <10 <10 <10 <10 640 320 640 640 Subclinical - -
19 <10 10 <10 <10 160 320 320 320 Subclinical - -
20 <10 <10 <10 <10 1280 2560 2560 5120 Subclinical - -
21 10 40 10 10 160 320 320 320 Subclinical - -
22 <10 20 10 10 40 40 80 80 Subclinical - -
23 <10 <10 <10 <10 20 <10 40 20 Subclinical - -
24 <10 <10 <10 10 160 160 640 640 Subclinical - -
25 <10 <10 <10 <10 40 20 40 80 Subclinical - -
26 <10 <10 10 10 10 <10 20 40 Subclinical - -
27 <10 10 20 20 <10 <10 80 160 Subclinical - -
28 10 <10 10 10 10 10 20 40 Subclinical - -
29 <10 <10 <10 <10 20 20 40 40 Subclinical - -
30 <10 <10 <10 <10 80 80 160 160 DF DV-1
31 <10 <10 <10 <10 640 320 640 320 DF DV-1
32 <10 <10 <10 <10 640 1280 1280 1280 DF Neg
33 <10 <10 10 10 1280 1280 640 1280 DF DV-3
34 <10 <10 <10 <10 320 320 640 1280 DF DV-3
35 10 <10 10 <10 1280 640 640 320 DF Neg
36 20 10 <10 10 2560 1280 2560 1280 DF Neg
37 <10 <10 <10 <10 160 320 640 320 DF DV-1
38 <10 <10 <10 <10 160 160 1280 640 DF Neg
39 <10 <10 10 10 320 320 1280 1280 DF DV-3
40 <10 <10 20 <10 80 80 640 160 DF DV-3
41 <10 <10 <10 <10 320 640 640 640 DF DV-3
42 <10 <10 <10 <10 640 1280 1280 1280 DF DV-2
43 <10 <10 <10 <10 80 20 40 40 DF DV-1
44 <10 <10 <10 <10 640 320 640 640 DF DV-3
45 <10 20 <10 <10 1280 1280 2560 1280 DF DV-3
46 <10 <10 <10 <10 1280 1280 1280 1280 DF DV-3
(Continued)
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Table 1. (Continued)
Subject No. HI Titer (pre)a HI Titer (post)b Clinical Outcome DV Type
(PCR)DV-1 DV-2 DV-3 DV-4 DV-1 DV-2 DV-3 DV-4
47 <10 10 <10 <10 1280 1280 2560 1280 DF DV-3
48 <10 <10 <10 <10 160 160 320 320 DF Neg
49 <10 <10 <10 <10 640 640 1280 2560 DHFIII DV-3
50 20 20 10 10 640 1280 2560 640 hDF DV-3
51 <10 <10 <10 10 640 320 1280 1280 hDF DV-1
aPrior to the 1998 season (January sample)
bFirst sample from a scheduled visit (June, August, or November) that showed a 4-fold rise in HI titer relative to the January sample
Abbreviations: DF, dengue fever; DHFIII, dengue hemorrhagic fever grade 3; DV-1-4, dengue virus types 1–4; hDF, hospitalized DF; HI, hemagglutination inhibition;
Neg, negative
https://doi.org/10.1371/journal.pntd.0006975.t001
Fig 1. Relative expression of cytokines in cell culture supernatants from stimulated pre-illness PBMC. PBMC from subjects who went on to
experience subclinical (n = 29) or symptomatic (n = 22) DENV infections were stimulated in vitro with anti-CD3 antibody (positive control),
live DENV-1, live DENV-2, live DENV-3, live DENV-4, or uninfected Vero cell supernatant (negative control). After 6–7 days, culture
supernatants were assessed by a multiplexed, bead-based array for quantification of 30 cytokines/chemokines/growth factors. Shown are three-
and five-fold changes up (light and dark blue, respectively) or down (grey and pink, respectively), relative to the negative control, of each listed
analyte. Each row represents responses from a single individual.
https://doi.org/10.1371/journal.pntd.0006975.g001
Pre-exposure cytokine profiles in dengue
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(S1 Fig). IL-2 was also only detectable in a handful of subjects (Fig 1), but this may reflect its
consumption during the culture by cells responding to DENV stimulation. While PBMC from
many subjects responded to DENV stimulation with production of IL-5, IL-8, IL-1RA, IP-10,
and MIG, no correlations were observed with respect to clinical outcome (Fig 1). The remain-
ing 12 cytokines showed patterns that appeared to differ by clinical outcome.
Increased production of cytokines in subjects with subclinical versus
symptomatic infections
Analyzing absolute concentrations of select cytokines, we found that levels of GM-CSF, IL-12,
IL-2R, MIP-1α, RANTES, and TNFα were significantly higher in DENV-stimulated culture
supernatants from subjects with subclinical versus symptomatic infections (Fig 2). While over-
all levels were low, GM-CSF and TNFα were significantly elevated after stimulation with
DENV-4 by subjects who later experienced subclinical DENV infections. Those subjects also
produced more IL-12 and IL-2R than symptomatic subjects, which was significant for DENV-
2, DENV-3, and DENV-4 stimulations. RANTES showed a similar pattern, except that subjects
with symptomatic infections appeared to down-regulate its expression relative to the negative
control. MIP-1α levels appeared naturally higher in subclinical subjects (in the absence of
stimulation) and remained so in the presence of DENV-2 and DENV-4 stimulation.
Additional cytokine responses indicated higher levels of DENV-specific expression in sub-
jects with subclinical infection compared to subjects with symptomatic infection, including
MIP-1β and VEGF (Fig 2B), although these observations did not reach statistical significance.
IFNγ responses were relatively modest in culture supernatants following DENV stimulation;
of the responders, however, the majority experienced subclinical infections (Fig 2C).
Previous data from our laboratory indicated significantly higher IFNγ responses in subjects
with subclinical infections [9]. As that study used a different assay format, we set up parallel
ICS assays using PBMC from the same subjects as used for the cytokine analysis above for
comparison. For these experiments, we stimulated PBMC with inactivated antigen overnight
and stained for the production of IFNγ, TNFα, and IL-2. Consistent with both the previous
study and the trends in cytokine levels noted above, we found higher frequencies of CD4+ and
CD8+ T cell producing IFNγ, TNFα, and IL-2 in response to DENV antigen stimulation in the
subjects with subclinical infections (Fig 3 and S2 Fig).
Increased production of IL-6, IL-15, and MCP-1 in subjects who
experienced symptomatic DENV infections
Levels of IL-6, IL-15, and MCP-1 were higher in response to DENV stimulation in subjects who
experienced DF/DHF versus those with subclinical infections (Fig 4). Most striking was IL-6
expression after DENV-1 stimulation. IL-6 production was highly up-regulated in DENV-1
stimulated cultures from all but one symptomatic subject, as compared to 17/29 (58.6%) sub-
jects with subclinical infections (Fig 4). One subject with symptomatic infection and four sub-
jects with subclinical infections who did not produce IL-6 in response to DENV-1 did have a
response to DENV-4, and one additional symptomatic subject produced IL-6 in response to
both DENV-1 and DENV-4. Neither DENV-2 nor DENV-3 stimulation resulted in substantial
up-regulation of IL-6 production, although DENV-3-stimulated wells showed a non-significant
trend toward higher levels of IL-6 in subjects with symptomatic infection (p = 0.061).
Discussion
Through a prospective study in Thailand we identified schoolchildren who experienced sub-
clinical DENV infections, and we compared their pre-existing cytokine profiles to peers who
Pre-exposure cytokine profiles in dengue
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experienced symptomatic infections. Using PBMC samples from approximately 4–7 months
prior to DENV exposure, we evaluated the production of 30 different cytokines, chemokines,
and growth factors in response to DENV stimulation in vitro, modeling interactions that
might occur in vivo during the subsequent DENV infection. Our analysis revealed that stimu-
lation of PBMC with all four types of DENV induced the production of cytokines, nine of
which significantly differed according to the clinical outcome of DENV infection. Six cyto-
kines/chemokines were more highly produced in PBMC of subjects who had subclinical infec-
tions, and three cytokines/chemokines were elevated in PBMC of subjects with symptomatic
Fig 2. Increased cytokine production in subjects who subsequently had subclinical versus symptomatic infections. (A) Levels (pg/mL) of GM-CSF, TNFα, IL-12,
IL-2R, MIP-1α, and RANTES were elevated in stimulated PBMC of subjects who subsequently developed subclinical (filled circles), as compared to symptomatic
(open squares), DENV infections. (B) MIP-1β and VEGF responses also showed slightly elevated production by subclinical cases, although they did not reach statistical
significance. (C) IFNγ expression was largely found only in subclinical cases. Each symbol represents responses from a single sample following stimulation with
uninfected supernatant (unstimulated; negative control, NC), a positive control stimulus (anti-CD3; PC), or live DENV-1 (DV-1), DENV-2 (DV-2), DENV-3 (DV-3),
or DENV-4 (DV-4). Median responses are represented by the grey bars. The dotted line indicates the lower level of detection for each analyte. The Wilcoxon rank-sum
test was used to compare cytokine production between the subclinical and symptomatic groups (�p<0.05, ��p<0.01, ���p<0.001, ����p<0.0001).
https://doi.org/10.1371/journal.pntd.0006975.g002
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infections. These data identified increased in vitro production of IL-12, IL-2R, MIP-1α,
RANTES, GM-CSF, and TNFα (possibly along with IFNγ, MIP-1β, and VEGF) as a “protec-
tive” immune profile and increased in vitro production of IL-6, IL-15, and MCP-1 as a “patho-
logic” immune profile.
The “protective” profile suggested by our data indicates roles for a robust innate anti-viral
response as well as activation of DENV-specific T cells. While we do not know which cell types
are responsible for production of these cytokines, the results of the ICS assay indicated that at
least some of the TNFα and IFNγ is secreted by T cells. DENV infection of dendritic cells has
been demonstrated in vitro to induce IL-12 production [13, 14], which presumably contributes
Fig 3. Higher frequencies of DENV-specific T cells in PBMC prior to subclinical versus symptomatic infections.
Intracellular IFNγ, TNFα, and IL-2 production by (A) CD4+ and (B) CD8+ T cells was measured by flow cytometry in
response to DENV-1-4 inactivated antigen stimulation of PBMC from Thai schoolchildren. Comparison groups are PBMC
from children who later developed subclinical (open symbols) or symptomatic (closed symbols) infections. The Wilcoxon
rank-sum test was used to compare cytokine production between the two groups (�p<0.05, ��p<0.01). Data are presented
relative to the negative control (responses to negative control stimulation were subtracted out).
https://doi.org/10.1371/journal.pntd.0006975.g003
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to T cell activation. Additionally, the CC chemokines MIP-1α, MIP-1β, and RANTES are
known to recruit monocytes/macrophages as well as lymphocytes, supporting a protective role
for T cell effectors. These data are in agreement with a study of experimentally DENV-chal-
lenged volunteers, which demonstrated higher frequencies of IFNγ-producing T cells in sub-
jects who were protected from disease versus those who were not [15].
Our group previously found increased TNFα production measured by ELISA in response
to stimulation with DENV antigen by PBMC collected before infection in children who were
hospitalized versus not hospitalized during the subsequent secondary DENV infection [16]. In
a later study involving a separate group of subjects, we found higher frequencies of IFNγ- and
IL-2–producing T cells measured by ICS staining after overnight stimulation with DENV anti-
gen among schoolchildren who subsequently developed subclinical infection, compared with
those who developed symptomatic, secondary DENV infection [9]. In both of the previous
studies, we stimulated PBMC in vitro with inactivated, DENV-infected Vero cell lysates that
was shown to predominantly stimulate CD4+ T cells. In the current study we set up both ICS
and 7-day culture assays, the latter using infectious DENV and expanding the number of cyto-
kines/chemokines tested. We found additional chemokines whose production was associated
with either subclinical or symptomatic DENV infections. Comparison of data from the two
different assays is complicated by the differences in stimulation conditions (infectious virus
versus inactivated DENV-infected Vero cell lysate), length of incubation time following
Fig 4. Higher IL-6, IL-15, and MCP-1 production in pre-exposure PBMC from symptomatic, compared to
subclinical, cases. IL-6, IL-15, and MCP-1 levels (pg/mL) were higher in culture supernatants of stimulated PBMC
from subjects who subsequently developed symptomatic (open squares), as compared to subclinical (filled circles),
DENV infections. Each symbol represents responses from a single sample following stimulation with uninfected
supernatant (unstimulated; negative control, NC), a positive control stimulus (anti-CD3; PC), or live DENV-1 (DV-1),
DENV-2 (DV-2), DENV-3 (DV-3), or DENV-4 (DV-4). Median responses are represented by the grey bars. The
dotted line indicates the upper or lower level of detection, as applicable, for each analyte. The Wilcoxon rank-sum test
was used to compare cytokine production between the subclinical and symptomatic groups (�p<0.05, ��p<0.01).
https://doi.org/10.1371/journal.pntd.0006975.g004
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stimulation (overnight versus 1 week), and assay method (intracellular cytokine staining ver-
sus cytokine analysis of cell culture supernatants); however, compiling the results from this
and previous studies suggests anti-viral cytokine production is generally beneficial.
In a human challenge model of influenza, IL-6, IL-15, and MCP-1, among others, were
highly upregulated in the first several days post-challenge in subjects who later developed
symptoms; while serum samples from subjects with no symptoms post-challenge did not have
elevations of these cytokines [17]. Those results are similar to our findings here in the context
of natural DENV infection. IL-15 is important for maintaining memory CD8+ T cells and NK
cells and is being used in cancer treatments to increase NK cell-mediated anti-tumor activity.
In hantavirus infection, however, IL-15-mediated activation of NK cells was shown to circum-
vent self-tolerance mechanisms leading to targeting of uninfected endothelial cells, demon-
strating a potential role in pathogenesis [18]. MCP-1 is involved in recruitment of monocytes/
macrophages and lymphocytes and has been implicated in diverting T cell responses from a
Th1 toward a Th2 type response [19]. Such a shift in responses would be consistent with the
lack of IFNγ production we saw in the current study in symptomatic subjects. Further study of
these cytokines and of the role of NK cells in particular in DENV infection is warranted.
The production of IL-6 in PBMC from all symptomatic individuals compared with only a
subset of subclinical individuals was a particularly striking finding in this study and suggests
its potential role in dengue disease pathogenesis. IL-6 levels have been shown to be elevated in
the sera of dengue patients and in several studies were significantly associated with more
severe disease [4, 5] IL-6 has various roles in immunity; it has been shown to increase the pro-
duction of anti-platelet or anti-endothelial cell auto-antibodies and tissue plasminogen activa-
tor [20, 21]. In vitro, DENV has been shown to induce the upregulation of TLR-2 and TLR-6
which stimulated the production of IL-6 and TNFα in PBMC [22] Recombinant DENV NS1
protein was also shown to stimulate IL-6 production in vitro [23]; however, this may not
explain completely our finding, as we saw type-specific differences in the induction of IL-6.
Identification of the cell subsets responsible for IL-6 production would be an important exten-
sion of our study and would further clarify the immunological pathways responsible.
Several limitations of the present study should be noted. We measured cytokine levels at a
single time point post-stimulation; assessing protein concentration at earlier and/or later time
points to create a kinetic profile of these cytokines might yield additional information.
Although we tested a wider array of cytokines compared to our earlier studies, most did not
show significant associations with clinical outcome, and many other cytokines were not
included in the panel. We also used a single representative virus strain for each DENV type;
thus, differences in cytokine production observed between the four types may reflect charac-
teristics of the specific strains used rather than apply generally to that type. Cytokine levels
were measured in the cell culture supernatants, and therefore we are not able to identify the
cell types responsible for their production. It is possible that some cytokines were secreted in
response to initial cytokine secretion by other cells, for example antigen-specific T cells,
highlighting the dynamic inter-cellular relationship of cytokine secretion and the resulting
complexity underlying interpretation of these data. Additionally, as our study population
included very few subjects who were hospitalized, we cannot determine if the “pathologic”
immune profile we observed is associated with more severe presentations of dengue. Finally,
our cohort study design limited us to PBMC samples from approximately 4–7 months prior to
DENV infection. Any changes in immune profiles during that time due to other, related infec-
tions or the process of waning immunity are therefore unknown. Future study designs will
attempt to close that temporal gap in order to address the influence of an individual’s current
immune profile on an incoming infection.
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Our results suggest that the type of DENV used for stimulation has a strong influence on
cytokine secretion. Although it is difficult to standardize the virus inocula across types, stimu-
lation with DENV-1 appeared to induce a different immune profile compared to stimulation
with DENV-2, -3, and -4. In symptomatic individuals, DENV-2, DENV-3, and in some cases
DENV-4 appeared to induce down-regulation of chemokine responses while stimulation with
DENV-1 increased IL-15, IL-6 and MCP-1 levels significantly. It should be noted that all of the
subjects included in the present study experienced DENV infection in 1998 and were in pri-
mary school during that year. Thus, the history of prior DENV infections in this study popula-
tion may be relatively uniform. We do not have data on previously infecting types for these
children, and as mentioned above extrapolating such information based on NAb titers is not
straightforward. This therefore limits our ability to analyze type-specific results in the context
of previous infection history. In other studies using PBMC collected from Thai children with
DENV infection we found preferential recognition of the DENV-1 variant of an epitope on the
NS3 protein by CD8+ T cells [24], and of DENV-1 virus by B cells [25]. Further studies will
therefore be needed to determine if these differences reflect an inherent quality of DENV-1,
genetic factors in the Thai population, or the immune history specific to this geographic region
and year.
In summary, our analysis of cytokine production by PBMC collected prior to DENV infec-
tion in response to DENV stimulation revealed a number of cytokines/chemokines whose pro-
duction was associated with the clinical outcome of infection. Our findings suggest that
profiles of “protective” or “pathologic” cytokines might contribute to an individual having a
subsequent subclinical or clinically apparent secondary DENV infection.
Supporting information
S1 Fig. Cytokines at low or undetectable levels in most subjects. PBMC from subjects who
went on to experience subclinical (n = 29) or symptomatic (n = 22) DENV infections were
stimulated in vitro with anti-CD3 antibody (positive control), live DENV-1, live DENV-2, live
DENV-3, live DENV-4, or uninfected Vero cell supernatant (negative control). After 6–7 days,
culture supernatants were assessed by a multiplexed, bead-based array for quantification of 30
cytokines/chemokines/growth factors. Shown are three- and five-fold changes up (light and
dark blue, respectively) or down (grey and pink, respectively), relative to the negative control,
of each listed analyte. Each row represents responses from a single individual.
(PDF)
S2 Fig. Example of ICS flow plots. The flow cytometry gating strategy to identify cytokine-
secreting T cells started with selecting lymphocytes, based on forward and side scatter profiles,
followed by singlet cells, dead cell dye exclusion (live cell gate), CD3+ cells, and finally CD4
+ or CD8+ T cell subsets. The bottom three rows of plots show CD4+ T cells expressing IFN-
gamma, IL-2, or TNF-alpha after no stimulation (negative control) or stimulation with
DENV-1 antigen (DENV-1 Ag) or PMA+ionomycin (positive control). Shown are plots from
a single representative subject.
(PDF)
S1 Table. Additional serological data on the cohort.
(PDF)
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